Full-Time

National Payer Manager

Posted on 5/10/2024

Telix Pharmaceuticals

Telix Pharmaceuticals

201-500 employees

Develops radiopharmaceuticals for cancer and rare diseases

Biotechnology

Senior

Remote in USA

Requirements
  • Bachelor’s degree in business or healthcare administration or relevant work experience
  • 5+ years of payer interaction to obtain coverage for new products
  • Experience with CMS regarding radiopharmaceutical diagnostic and therapeutic products
  • Proven experience in communicating with government and commercial payers
  • Experience in analyzing healthcare data
  • Proven experience demonstrating an understanding of the US reimbursement structure
Responsibilities
  • Obtain positive coverage guidelines for Telix products with government and commercial payers by building relationships with key stakeholders in these accounts
  • Understand and deliver the Value Proposition in order to grow product portfolio and indication access
  • Manage relationships with State Societies
  • Work with CMS and develop strategies to build collaboration
  • Present payer updates to the internal stakeholder team
  • Present updated payer updates to external partners
  • Analyze retrospective payer landscape and advise strategies regarding payors. Modeling these impacts through life-cycle management
  • Report current payer trends that impact Telix current and future products
  • Training of Market Access teams regarding payer groups and impact to customers
  • Lead cross functional payer discussions

Telix Pharmaceuticals develops and commercializes diagnostic and therapeutic radiopharmaceuticals for oncology and rare diseases, utilizing targeted radiation for personalized therapy and disease imaging. The company's pipeline includes products for prostate, kidney, brain, and hematologic cancers, supported by global regulatory approvals and a secure supply chain.

Company Stage

Grant

Total Funding

$63.5M

Headquarters

North Melbourne, Australia

Founded

2015

Growth & Insights
Headcount

6 month growth

20%

1 year growth

48%

2 year growth

135%